12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EVP-6124: Phase III started

EnVivo began a pair of double-blind, placebo-controlled, international Phase III trials in about 700 patients each to evaluate 2 doses of oral EVP-6124 once daily for 26 weeks added to chronic, stable, atypical antipsychotic therapy. EnVivo has exclusive, worldwide rights to EVP-6124...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >